Belvedere Trading’s Quince Therapeutics QNCX Stock Holding History

Belvedere Trading’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-60	Closed	-$13.4K	–	953
2023 Q3	$13.4K	Hold	60	–	–	﹤0.01%	531
2023 Q2	$18.1K	Hold	60	–	–	﹤0.01%	671
2023 Q1	$18.7K	Buy	+60	New	+$11.7K	﹤0.01%	715
2021 Q4	–	Sell	-114	Closed	-$1.34M	–	586
2021 Q3	$1.34M	Buy	114 +64	+128%	+$1.02M	0.04%	40
2021 Q2	$578K	Buy	+50	New	+$419K	0.04%	95

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belvedere Trading's QNCX Position: Q1 2026 in Review

Belvedere Trading opened a new position in Quince Therapeutics (QNCX) in Q1 2026: 65 shares worth $1.32K. The stake represents ﹤0.01% of the portfolio and ranks #715 among its holdings.

43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Belvedere Trading held 65 shares of Quince Therapeutics worth $1.32K as of Q1 2026.
Quince Therapeutics was a new Belvedere Trading position in Q1 2026.
Quince Therapeutics made up ﹤0.01% of Belvedere Trading's portfolio in Q1 2026, its #715 holding.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.